Measles Immunity Status of Greek Population after the Outbreak in 2017–2018: Results from a Seroprevalence National Survey
Abstract
:1. Introduction
2. Materials and Methods
2.1. Study Design and Participants
2.2. Laboratory Analysis
2.3. Statistical Analysis
2.4. Ethical Statement
3. Results
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- van Panhuis, W.G.; Grefenstette, J.; Jung, S.Y.; Chok, N.S.; Cross, A.; Eng, H.; Lee, B.Y.; Zadorozhny, V.; Brown, S.; Cummings, D.; et al. Contagious Diseases in the United States from 1888 to the Present. N. Engl. J. Med. 2013, 369, 2152–2158. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zhou, F.; Shefer, A.; Wenger, J.; Messonnier, M.; Wang, L.Y.; Lopez, A.; Moore, M.; Murphy, T.V.; Cortese, M.; Rodewald, L. Economic Evaluation of the Routine Childhood Immunization Program in the United States, 2009. Pediatrics 2014, 133, 577–585. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Benefits from Immunization during the Vaccines for Children Program Era—United States, 1994–2013. Available online: https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6316a4.htm (accessed on 12 April 2023).
- Measles. Available online: https://www.who.int/news-room/fact-sheets/detail/measles?gclid=CjwKCAiA9NGfBhBvEiwAq5vSy0LoZb6eUZCrIeVfmg9FcNW4VdNHQ59bwBZj0A0edN3FVE1Nbgfu4xoCFIUQAvD_BwE (accessed on 12 April 2023).
- History of Measles Vaccination. Available online: https://www.who.int/news-room/spotlight/history-of-vaccination/history-of-measles-vaccination?topicsurvey=ht7j2q)&gclid=Cj0KCQiAutyfBhCMARIsAMgcRJRuqLNP-QtuKj1VVPoeHCzxgEtm-NsexSb7H-bJSaOWKg9qUQV3EDUaAnF3EALw_wcB (accessed on 12 April 2023).
- Moss, W.J.; Shendale, S.; Lindstrand, A.; O’Brien, K.L.; Turner, N.; Goodman, T.; Kretsinger, K. Feasibility Assessment of Measles and Rubella Eradication. Vaccine 2021, 39, 3544–3559. [Google Scholar] [CrossRef] [PubMed]
- Wilder-Smith, A.B.; Qureshi, K. Resurgence of Measles in Europe: A Systematic Review on Parental Attitudes and Beliefs of Measles Vaccine. J. Epidemiol. Glob. Health 2020, 10, 46. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Panagiotopoulos, T.; Antoniadou, I.; Valassi-Adam, E.; Berger, A. Increase in Congenital Rubella Occurrence after Immunisation in Greece: Retrospective Survey and Systematic Review. BMJ Br. Med. J. 1999, 319, 1462. [Google Scholar] [CrossRef] [Green Version]
- Σημεία, Σ. Τμήμα Επιδημιολογικής Επιτήρησης Και Παρέμβασης ΕΠΙΔHΜΙOΛOΓΙΚA ΔΕΔOΜΕΝA ΓΙA ΤHΝ ΙΛAΡA ΣΤHΝ ΕΛΛAΔA 2018 (ΣΥΣΤHΜA ΥΠOΧΡΕΩΤΙΚHΣ ΔHΛΩΣHΣ ΝOΣHΜAΤΩΝ). Available online: https://eody.gov.gr/wp-content/uploads/2019/04/ilara_epidimiologika_dedomena_2018.pdf (accessed on 12 April 2023).
- Ιλαρά—Εθνικός Oργανισμός Δημόσιας Υγείας. Available online: https://eody.gov.gr/disease/ilara/ (accessed on 12 April 2023).
- Gianniki, M.; Siahanidou, T.; Botsa, E.; Michos, A. Measles Epidemic in Pediatric Population in Greece during 2017–2018: Epidemiological, Clinical Characteristics and Outcomes. PLoS ONE 2021, 16, e0245512. [Google Scholar] [CrossRef]
- Measles Reported Cases and Incidence. Available online: https://immunizationdata.who.int/pages/incidence/measles.html?CODE=GRC&YEAR= (accessed on 12 April 2023).
- Σμιμα Επιδθμιολογικισ Επιτιρθςθσ Και Παρζμβαςθσ ΕΠΙΔHΜΙOΛOΓΙΚA ΔΕΔOΜΕΝA ΓΙA ΣHΝ ΙΛAΡA ΣHΝ ΕΛΛAΔA. Available online: https://eody.gov.gr/wp-content/uploads/2019/01/ilara_epidimiologika_dedomena_2017.pdf (accessed on 12 April 2023).
- Τμήμα Επιδημιολογικής Επιτήρησης Και Παρέμβασης ΕΠΙΔHΜΙOΛOΓΙΚA ΔΕΔOΜΕΝA ΓΙA ΤHΝ ΙΛAΡA ΣΤHΝ ΕΛΛAΔA. Available online: https://eody.gov.gr/wp-content/uploads/2019/07/ilara-1.1-30.6.2019.pdf (accessed on 12 April 2023).
- Vaccination Coverage for Second Dose of a Measles-Containing Vaccine, EU/EEA. 2018. Available online: https://www.ecdc.europa.eu/en/publications-data/vaccination-coverage-second-dose-measles-containing-vaccine-eueea-2018 (accessed on 12 April 2023).
- Vaccination Coverage for the First Doses of Measles and Rubella Containing Vaccine by Country, EU/EEA. 2018. Available online: https://www.ecdc.europa.eu/en/publications-data/vaccination-coverage-first-doses-measles-and-rubella-containing-vaccine-country-0 (accessed on 12 April 2023).
- Georgakopoulou, T.; Menegas, D.; Katsioulis, A.; Theodoridou, M.; Kremastinou, J.; Hadjichristodoulou, C. A Cross-Sectional Vaccination Coverage Study in Preschool Children Attending Nurseries-Kindergartens: Implications on Economic Crisis Effect. Hum. Vaccines Immunother. 2017, 13, 190–197. [Google Scholar] [CrossRef] [Green Version]
- Andrie, E.K.; Sakellari, E.; Barbouni, A.; Tsitsika, A.K.; Lagiou, A. Vaccination Coverage during Childhood and Adolescence among Undergraduate Health Science Students in Greece. Children 2022, 9, 1553. [Google Scholar] [CrossRef] [PubMed]
- Papamichail, D.; Petraki, I.; Arkoudis, C.; Terzidis, A.; Smyrnakis, E.; Benos, A.; Panagiotopoulos, T. Low Vaccination Coverage of Greek Roma Children amid Economic Crisis: National Survey Using Stratified Cluster Sampling. Eur. J. Public Health 2017, 27, 318. [Google Scholar] [CrossRef] [Green Version]
- Maltezou, H.C.; Karantoni, H.; Petrikkos, P.; Georgota, P.; Katerelos, P.; Liona, A.; Tsagarakis, S.; Theodoridou, M.; Hatzigeorgiou, D. Vaccination Coverage and Immunity Levels against Vaccine-Preventable Diseases in Male Air Force Recruits in Greece. Vaccine 2020, 38, 1181–1185. [Google Scholar] [CrossRef]
- Gioula, G.; Exindari, M.; Melidou, A.; Minti, F.; Sidiropoulou, E.; Dionisopoulou, S.; Kiriazi, M.; Tsintarakis, E.; Malisiovas, N. Seroprevalence of measles in Northern Greece. Acta Microbiol. Hell. 2017, 62, 145–150. [Google Scholar]
- Manganas, C.; Sophia, K.; Myria, D.; Aikaterini, P.; Maria, X. Seroprevalence for Measles Antibodies among Multi-Transfused Patients with Hemoglobinopathies: The Experience of a Thalassemia and Sickle Cell Department in Seroprevalence for Measles Antibodies among Multi-Transfused Pa-Tients with Hemoglobinopathies: The Experience of a Thalassemia and Sickle Cell Department in Greece. J. Prev. Infect. Control. 2022. [Google Scholar] [CrossRef]
- Nardone, A.; Miller, E. Serological Surveillance of Rubella in Europe: European Sero-Epidemiology Network (ESEN2). Eurosurveillance 2004, 9, 5–7. [Google Scholar] [CrossRef] [PubMed]
- Gieles, N.C.; Mutsaerts, E.A.M.L.; Kwatra, G.; Bont, L.; Cutland, C.L.; Jones, S.; Moultrie, A.; Madhi, S.A.; Nunes, M.C. Measles Seroprevalence in Pregnant Women in Soweto, South Africa: A Nested Cohort Study. Clin. Microbiol. Infect. 2020, 26, 515.e1–515.e4. [Google Scholar] [CrossRef] [PubMed]
- Wang, Q.; Wang, W.; Winter, A.K.; Zhan, Z.; Ajelli, M.; Trentini, F.; Wang, L.; Li, F.; Yang, J.; Xiang, X.; et al. Long-Term Measles Antibody Profiles Following Different Vaccine Schedules in China, a Longitudinal Study. Nat. Commun. 2023, 14, 1746. [Google Scholar] [CrossRef] [PubMed]
- Statistics—ELSTAT. Available online: https://www.statistics.gr/en/statistics/-/publication/SPO18/ (accessed on 13 April 2023).
- Copenhagen The Expanded Programme on Immunization in the European Region of WHO Measles A Strategic Framework for the Elimination of Measles in the European Region. Available online: https://apps.who.int/iris/bitstream/handle/10665/108278/E68405.pdf?sequence=1&isAllowed=y (accessed on 12 April 2023).
- Friedrich, N.; Poethko-Müller, C.; Kuhnert, R.; Matysiak-Klose, D.; Koch, J.; Wichmann, O.; Santibanez, S.; Mankertz, A. Seroprevalence of Measles-, Mumps-, and Rubella-Specific Antibodies in the German Adult Population—Cross-Sectional Analysis of the German Health Interview and Examination Survey for Adults (DEGS1). Lancet Reg. Health Eur. 2021, 7, 100128. [Google Scholar] [CrossRef]
- González-Escalada, A.; García-García, L.; Viguera-Ester, P.; Marín-García, P.; García, J.; Gil-De-Miguel, A.; Gil-Prieto, R. Human Vaccines & Immunotherapeutics Seroprevalence of Antibodies against Measles, Rubella, Mumps, Varicella-Zoster, and B. Pertussis in Young Adults of Madrid, Spain. Hum. Vaccines Immunother. 2013, 9, 1918–1925. [Google Scholar] [CrossRef] [Green Version]
- Ask the Experts: Measles, Mumps, and Rubella (MMR) Vaccines. Available online: https://www.immunize.org/askexperts/experts_mmr.asp (accessed on 13 April 2023).
- Measles in the EU/EEA: Current Outbreaks, Latest Data and Trends—January 2018. Available online: https://www.ecdc.europa.eu/en/news-events/measles-eueea-current-outbreaks-latest-data-and-trends-january-2018 (accessed on 13 April 2023).
- Georgakopoulou, T.; Horefti, E.; Vernardaki, A.; Pogka, V.; Gkolfinopoulou, K.; Triantafyllou, E.; Tsiodras, S.; Theodoridou, M.; Mentis, A.; Panagiotopoulos, T. Ongoing Measles Outbreak in Greece Related to the Recent European-Wide Epidemic. Epidemiol. Infect. 2018, 146, 1692–1698. [Google Scholar] [CrossRef]
- Nearly 40 Million Children Are Dangerously Susceptible to Growing Measles Threat. Available online: https://www.who.int/news/item/23-11-2022-nearly-40-million-children-are-dangerously-susceptible-to-growing-measles-threat (accessed on 13 April 2023).
- MMR Vaccines and Autism. Available online: https://www.who.int/groups/global-advisory-committee-on-vaccine-safety/topics/mmr-vaccines-and-autism (accessed on 13 April 2023).
- Tafuri, S.; Bianchi, F.P.; Stefanizzi, P.; De Nitto, S.; Maria, A.; Larocca, V.; Germinario, C.; Tafuri, S. The Journal of Infectious Diseases Long-Term Immunogenicity of Measles Vaccine: An Italian Retrospective Cohort Study. J. Infect. Dis. 2020, 221, 721–729. [Google Scholar] [CrossRef] [Green Version]
- Poethko-Müller, C.; Mankertz, A. Sero-Epidemiology of Measles-Specific IgG Antibodies and Predictive Factors for Low or Missing Titres in a German Population-Based Cross-Sectional Study in Children and Adolescents (KiGGS). Vaccine 2011, 29, 7949–7959. [Google Scholar] [CrossRef] [Green Version]
- Tasika, E.; Farmaki, E.; Roilides, E.; Antachopoulos, C. Implementation of the Greek National Immunization Program among Nursery Attendees in the Urban Area of Thessaloniki. Hippokratia 2019, 23, 147. [Google Scholar] [PubMed]
- Anichini, G.; Gandolfo, C.; Fabrizi, S.; Miceli, G.B.; Terrosi, C.; Savellini, G.G.; Prathyumnan, S.; Orsi, D.; Battista, G.; Cusi, M.G. Seroprevalence to Measles Virus after Vaccination or Natural Infection in an Adult Population, in Italy. Vaccines 2020, 8, 66. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bianchi, F.P.; Mascipinto, S.; Stefanizzi, P.; De Nitto, S.; Germinario, C.; Tafuri, S. Long-Term Immunogenicity after Measles Vaccine vs. Wild Infection: An Italian Retrospective Cohort Study. Hum. Vaccines Immunother. 2021, 17, 2078–2084. [Google Scholar] [CrossRef]
- Ristić, M.; Milošević, V.; Medić, S.; Malbaša, J.D.; Rajčević, S.; Boban, J.; Petrović, V. Sero-Epidemiological Study in Prediction of the Risk Groups for Measles Outbreaks in Vojvodina, Serbia. PLoS ONE 2019, 14, e0216219. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Smetana, J.; Chlibek, R.; Hanovcova, I.; Sosovickova, R.; Smetanova, L.; Gal, P.; Dite, P. Decreasing Seroprevalence of Measles Antibodies after Vaccination—Possible Gap in Measles Protection in Adults in the Czech Republic. PLoS ONE 2017, 12, 170257. [Google Scholar] [CrossRef] [Green Version]
- Ruggieri, A.; Anticoli, S.; D’ambrosio, A.; Giordani, L.; Viora, M. Monographic Section The Influence of Sex and Gender on Immunity, Infection and Vaccination. Ann. Ist. Super. Sanita 2016, 52, 198–204. [Google Scholar] [CrossRef]
- Mikhail Kostinov, P.; Pavel Zhuravlev, I.; Nikolay Filatov, N.; Aristitsa Kostinova, M.; Valentina Polishchuk, B.; Anna Shmitko, D.; Cyrill Mashilov, V.; Anna Vlasenko, E.; Alexey Ryzhov, A.; Anton Kostinov, M. Gender Differences in the Level of Antibodies to Measles Virus in Adults. Vaccines 2021, 9, 494. [Google Scholar] [CrossRef]
- Tenth Meeting of the European Regional Verification Commission for Measles and Rubella Elimination. 2022. Available online: https://www.who.int/europe/publications/i/item/WHO-EURO-2022-6093-45858-66035 (accessed on 12 April 2023).
Positive (N) | Negative (N) | Equivocal (N) | Total | Crude Seroprevalence | Adjusted Seroprevalence * | 95% CI | Sig.** | Antibodies Concentration of Seropositive Participants (mIU/mL) | 95% CI | Sig. | ||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Overall | 3558 | 327 | 87 | 3972 | 89.6% | 89.8% | 88.8% | 90.8% | - | 672.9 | 662.7 | 683.1 | - | |
Sex | Male | 1382 | 132 | 27 | 1541 | 89.7% | 89.2% | 87.6% | 90.8% | 0.783 C | 692.9 | 674.0 | 711.8 | 0.003 M-W |
Female | 1974 | 180 | 54 | 2208 | 89.4% | 89.8% | 88.5% | 91.1% | 656.9 | 645.9 | 667.9 | |||
Age groups | 1–24 | 810 | 110 | 35 | 955 | 84.8% | 84.4% | 81.9% | 86.8% | <0.001 C | 640.5 | 609.4 | 671.6 | <0.001 K-W |
25–54 | 1420 | 160 | 39 | 1619 | 87.7% | 87.6% | 85.9% | 89.3% | 632.1 | 619.0 | 645.3 | |||
55–64 | 555 | 25 | 4 | 584 | 95.0% | 95.6% | 93.7% | 97.4% | 744.2 | 723.7 | 764.6 | |||
65–79 | 486 | 17 | 6 | 509 | 95.5% | 94.9% | 93.0% | 96.7% | 749.6 | 730.2 | 769.0 | |||
80+ | 168 | 6 | 2 | 176 | 95.5% | 95.4% | 92.3% | 98.6% | 722.4 | 687.3 | 757.4 | |||
Age groups | 1–40 | 1149 | 165 | 54 | 1368 | 84.0% | 83.4% | 81.6% | 85.7% | <0.001 C | 616.5 | 593.4 | 639.6 | <0.001 M-W |
≥41 | 1513 | 62 | 18 | 1593 | 95.0% | 94.9% | 93.7% | 95.9% | 730.0 | 718.0 | 742.1 | |||
Large urban areas (>500,000) | 1532 | 152 | 27 | 1711 | 89.5% | 90.3% | 84.4% | 94.1% | 0.991 C | 681.3 | 663.7 | 698.8 | 0.163 M-W | |
Rest of country | 1949 | 170 | 58 | 2177 | 89.5% | 89.0% | 84.4% | 92.1% | 665.6 | 653.4 | 677.8 | |||
Islands | 487 | 39 | 11 | 537 | 90.7% | 90.7% | 80.5% | 95.4% | 0.523 C | 665.2 | 642.7 | 687.7 | 0.899 M-W | |
Mainland | 2994 | 283 | 74 | 3351 | 89.3% | 89.2% | 85.3% | 92.4% | 673.7 | 662.2 | 685.2 |
Region (NUTS Level 2) | Positive (N) | Negative (N) | Equivocal (N) | Total | Crude Seroprevalence | Adjusted Seroprevalence | 95% CI | Sig.** | Antibodies Concentration of Seropositive Participants (mIU/mL) | 95% CI | Sig. | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Attica | 1188 | 132 | 10 | 1330 | 89.3% | 89.8% * | 88.1% | 91.4% | <0.001 C | 672.8 | 651.5 | 694.0 | <0.001 K-W |
Central Greece | 204 | 19 | 4 | 227 | 89.9% | 90.1% | 86.2% | 93.6% | 693.1 | 658.5 | 727.7 | ||
Thessaly | 231 | 19 | 6 | 256 | 90.2% | 90.7% * | 86.4% | 95.0% | 642.9 | 608.4 | 677.4 | ||
Western Greece | 200 | 22 | 12 | 234 | 85.5% | 85.9% * | 81.4% | 90.4% | 636.9 | 605.3 | 668.5 | ||
Epirus | 97 | 4 | 5 | 106 | 91.5% | 90.5% * | 83.9% | 97.0% | 692.5 | 570.0 | 814.9 | ||
Crete | 261 | 23 | 5 | 289 | 90.3% | 90.2% | 86.7% | 93.6% | 641.5 | 611.4 | 671.6 | ||
Central Macedonia | 586 | 38 | 24 | 648 | 90.4% | 91.3% * | 88.8% | 93.8% | 705.1 | 685.2 | 725.1 | ||
Ionian Islands | 64 | 10 | 2 | 76 | 84.2% | 85.8% | 78.0% | 93.6% | 686.1 | 627.3 | 745.0 | ||
North Aegean | 68 | 3 | 1 | 72 | 94.4% | 95.7% * | 91.0% | 100% | 645.7 | 584.9 | 706.5 | ||
South Aegean | 94 | 3 | 3 | 100 | 94.0% | 91.1% | 85.6% | 96.7% | 730.9 | 676.9 | 784.8 | ||
Peloponnese | 220 | 9 | 0 | 229 | 96.1% | 95.6% * | 92.6% | 98.7% | 695.3 | 661.2 | 729.4 | ||
Western Macedonia | 80 | 14 | 3 | 97 | 82.5% | 85.2% | 78.1% | 92.3% | 652.5 | 602.8 | 702.2 | ||
Eastern Macedonia and Thrace | 189 | 27 | 10 | 226 | 83.6% | 84.6% * | 79.9% | 89.4% | 610.7 | 576.1 | 645.3 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Nasika, A.; Bogogiannidou, Z.; Mouchtouri, V.A.; Dadouli, K.; Kyritsi, M.A.; Vontas, A.; Voulgaridi, I.; Tsinaris, Z.; Kola, K.; Matziri, A.; et al. Measles Immunity Status of Greek Population after the Outbreak in 2017–2018: Results from a Seroprevalence National Survey. Vaccines 2023, 11, 1220. https://doi.org/10.3390/vaccines11071220
Nasika A, Bogogiannidou Z, Mouchtouri VA, Dadouli K, Kyritsi MA, Vontas A, Voulgaridi I, Tsinaris Z, Kola K, Matziri A, et al. Measles Immunity Status of Greek Population after the Outbreak in 2017–2018: Results from a Seroprevalence National Survey. Vaccines. 2023; 11(7):1220. https://doi.org/10.3390/vaccines11071220
Chicago/Turabian StyleNasika, Asimina, Zacharoula Bogogiannidou, Varvara A. Mouchtouri, Katerina Dadouli, Maria A. Kyritsi, Alexandros Vontas, Ioanna Voulgaridi, Zafeiris Tsinaris, Konstantina Kola, Alexia Matziri, and et al. 2023. "Measles Immunity Status of Greek Population after the Outbreak in 2017–2018: Results from a Seroprevalence National Survey" Vaccines 11, no. 7: 1220. https://doi.org/10.3390/vaccines11071220